3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Recurrence
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Interventions
tislelizumab
2
sugemalimab
2
pegaspargase
2
IMC-001
2
Gemcitabine
2
tipifarnib
1
relatlimab
1
ontuxizumab
1
gemcitabine-oxaliplatin regimen
1
camrelizumab
1
WW Domain-Containing Oxidoreductase
1
Vitamin B 12
1
Sensitivity and Specificity
1
Oxaliplatin
1
Nivolumab
1
Mannose-Binding Lectin
1
Ice
1
Folic Acid
1
Commerce
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Extranodal NK-T-Cell
×
Ice
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled